stockrowKiniksa Pharmaceuticals International, plc (KNSA) vs Neurocrine Biosciences, Inc. (NBIX)
- Kiniksa Pharmaceuticals International, plc KNSA 88.50 −7.93%
- Neurocrine Biosciences, Inc. NBIX 160.47 −3.36%
Kiniksa Pharmaceuticals International, plc and Neurocrine Biosciences, Inc. are both Drug Manufacturers Specialty & Generic companies. Neurocrine Biosciences, Inc. is the larger, with a market value of $16.2B against $6.9B — 2.3× the size. Neurocrine Biosciences, Inc. trades at the lower P/E: 23.0× against 62.1×. Kiniksa Pharmaceuticals International, plc grew revenue faster over the last twelve months: 58.2% against 38.0%. Neurocrine Biosciences, Inc. has the higher net margin (19.0% vs 11.6%) and the lower return on invested capital (17.7% vs 57.7%). Across the 20 metrics below, Neurocrine Biosciences, Inc. leads on 15 and Kiniksa Pharmaceuticals International, plc on 5.
Valuation
Profitability
| Metric | KNSA | NBIX | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 90.16% | 97.75% | 53.51% |
| Operating margin | 13.79% | 23.96% | 0.00% |
| Net margin | 11.58% | 18.98% | (2.45%) |
| Free cash flow margin | 20.85% | 28.09% | 0.00% |
| Return on equity | 17.59% | 20.41% | (0.80%) |
| Return on assets | 12.92% | 14.20% | (1.67%) |
| Return on invested capital | 57.65% | 17.65% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack